Benefits of bisphosphonates outweigh risks, despite links to atypical femural fractures.
A review of recent evidence linking bisphosphonate (BP) drugs used to treat osteoporosis with atypical femural fractures (AFFs) has found that long-term use of the drugs increases the risk of these rare fractures.